Inside the White House with D.C.'s most wired reporter. Sign up for Mike Allen's Axios AM.


Nearly 30 drugmakers to raise prices in 2019

Swiss headquarters Novartis
The Swiss headquarters of Novartis. Photo: Sebastien Bozon/AFP/Getty Images

Nearly 30 drugmakers have taken steps to raise the price of their drugs in January, Reuters reports.

The big picture: The industry had said it was halting price increases under pressure from the Trump administration.

For example: Novartis plans to raise prices on more than 100 indications of over 30 different drugs. These include a multiple sclerosis drug, an arthritis treatment and a leukemia treatment.

  • A spokesperson said that the company will be raising list prices on 14% of the drugs it sells in the U.S., with an average list price increase of 4.7%. But rebates and discounts will result in a 5% net price decrease across the company's U.S. portfolio.

Our thought bubble: This isn't surprising. At this point, no one should think that drug companies are going to voluntarily stop raising list prices.

Go deeper: The drug pricing maze

More stories loading.